Charon Robin Ganellin
Born Jan 25 1934
Pharmacologically Active Guanidine Compounds
Tagamet - Cimetidine
Patent Number(s) 3,950,333; 4,024,271
Graham J. Durant, John Colin Emmett, and C. Robin Ganellin led the SmithKline Beecham Corporation's research team that discovered the H2 receptor class of drugs, including cimetidine, which inhibits the production of stomach acid.
Durant, Emmett, and Ganellin's work, begun in 1964 and done in collaboration with Nobel laureate biologist Sir James Black, established a physiological role for histamine in the control of gastric acid secretions-the major cause of ulcers.
The World Health Organization lists cimetidine, known by the brand name Tagamet, as one of the world's most essential drugs for its ability to heal stomach ulcers without surgery.
Ganellin was born in London, England, and studied chemistry at Queen Mary College, London and at the Massachusetts Institute of Technology. He is currently with SmithKline and French professor of medicinal chemistry at University College London, where he is also director of the Upjohn European Discovery Unit. Ganellin is named as co-inventor on more than 100 U.S. patents.